Parallel Advisors
PRVB

Parallel Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Parallel Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,161
Closed -$7K – 3390
2021
Q4 		$7K Buy
1,161
+852
+276% +$5.41K ﹤0.01% 2290
2021
Q3 		$2K Buy
+309
New +$1.99K ﹤0.01% 2769

Other funds holding PRVB

Sessa Capital
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DCM
DG Capital Management New York $475M AUM 36.12% 1-Year Est. Return

Parallel Advisors's PRVB Position: Q1 2022 in Review

Parallel Advisors sold out of Provention Bio, Inc. Common Stock (PRVB) in Q1 2022, closing a stake of 1,161 shares — an estimated $7K sold.

Parallel Advisors first reported a position in PRVB in Q3 2021 and held it in 2 quarters. The position peaked at $7K in Q4 2021. 113 funds tracked by Wall St. Rank hold PRVB as of Q1 2022.

  • Parallel Advisors reported no remaining Provention Bio, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Parallel Advisors sold 1,161 Provention Bio, Inc. Common Stock shares in Q1 2022, an estimated $7K.
  • Parallel Advisors first reported a position in Provention Bio, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Parallel Advisors's Provention Bio, Inc. Common Stock position peaked at $7K in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q1 2022.

Based on Parallel Advisors's 13F filing for Q1 2022, filed 28 Apr 2022.